Ibere Pharmaceuticals Overview
Ibere Pharmaceuticals (IBER) has a P/E ratio of 29.94, below the sector sector average of 35.6.
Get informed when a big investor buys or sells
+ Follow29.94
The P/E ratio compares a company's stock price to its earnings per share. A lower P/E ratio may indicate that the stock is undervalued.
Ibere Pharmaceuticals's p/e ratio stands at 29.94. That is below the sector sector average of 35.6. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.
Ibere Pharmaceuticals sits lower the its sector benchmark (35.6) with a P/E ratio of 29.94. That is roughly 15.9% below the sector mean. Peer context matters because what looks expensive or cheap in absolute terms can be normal for the sector.
Whether 29.94 is attractive depends on Ibere Pharmaceuticals's earnings outlook, competitive position, and how peers are valued. Investors typically ask: is growth accelerating, are margins stable, and is the multiple expanding or compressing over time? The history and comparison charts below are built for those checks.
The history chart shows how Ibere Pharmaceuticals's P/E ratio evolved across reporting periods, while the comparison chart places IBER next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.
